Skip to Content

CVS Health Corp CVS

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

CVS Delivers Strong Q1 and Increases 2021 Outlook; Shares Remain Undervalued

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat CVS Health turned in first-quarter results that beat FactSet consensus and raised its 2021 EPS outlook slightly. At first glance, we do not anticipate changing our $92 fair value estimate materially based on this announcement, but CVS shares still appear moderately undervalued, in our opinion.

Read Full Analysis

Company Profile

Business Description

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with over 23 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Contact
One CVS Drive
Woonsocket, RI, 02895
T +1 401 765-1500
Sector Healthcare
Industry Healthcare Plans
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Classic Growth
Employees 300,000

Related